Education
About Us
Working with TipRanks
Follow Us
Haemonetics (HAE)
:HAE
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.30 - $94.99
Previous CloseN/A
Volume53.78K
Average Volume (3M)576.97K
Market Cap
$3.64B
Enterprise Value$4.10B
Total Cash (Recent Filing)$306.76M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)17.0
Beta0.89
Next Earnings
Nov 05, 2025EPS Estimate
1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding48,036,995
10 Day Avg. Volume544,046
30 Day Avg. Volume576,966
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit5.48
Enterprise Value/Ebitda14.65
Forecast
1Y Price Target
$82.33Price Target Upside48.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Market OutlookThe outlook for the plasma space remains solid with positive comments regarding demand for plasma-derived therapies from multiple plasma fractionators.
Product InnovationBlood Management Technology showed impressive growth driven by new product launches and account openings.
Revenue PerformanceThe Plasma segment outperformed expectations, contributing to a revenue beat for Haemonetics.
Bears Say
Competitive PressuresInterventional Technology segment revenue was below expectations, with competitive pressures affecting growth prospects.
Leadership And StrategyIncreased competition for VASCADE has prompted leadership and sales force changes at HAE.
Revenue GuidanceManagement provided FY26 revenue and EPS guidance that was below consensus at the midpoints.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $55.30 and its highest was $94.98 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $3.64B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Nov 05, 2025 which is in 88 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Aug 07, 2025. The company reported $1.1 earnings per share for the quarter, beating the consensus estimate of $1.008 by $0.092.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.13.
How many shares outstanding does Haemonetics have?
Haemonetics has 48,036,995 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.1 in its last earnings report, beating expectations of $1.008. Following the earnings report the stock price went down -26.58%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.33 (48.00% Upside)
$82.33 (48.00% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 53.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.10%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
-3.10%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation, headquartered in Braintree, Massachusetts, is a global healthcare company specializing in blood management solutions. The company operates across multiple sectors, including blood and plasma collection, hospital transfusion management, and hemostasis management. Haemonetics offers a range of products and services designed to improve patient care and reduce the cost of healthcare delivery. Its core offerings include automated blood collection devices, software solutions for blood centers, and products for blood component separation and storage.
HAE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong revenue growth in the hospital segment and significant margin expansion, but it also faced challenges with the decline in Plasma revenue due to CSL transition and ongoing issues in China's market.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$82.33
▲(48.00% Upside)
Technical Analysis
Ownership Overview
1.33% Insiders
41.94% Mutual Funds
1.31% Other Institutional Investors
29.33% Public Companies and
Individual Investors